Svein Arild Mathisen

Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.

Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.

Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.

Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.

Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.

Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.

Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.

Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.